Studies of pharmacokinetics and therapeutic effects of glucocorticoids entrapped in liposomes after intraarticular application in healthy rabbits and in rabbits with antigen-induced arthritis

Bonanomi, M. H.; Velvart, M.; Stimpel, Michael; Roos, Kristine; Fehr, K; Weder, H. G.

doi:10.1007/bf00541378

Cited by 58 publications

(27 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This was supported by a study by Bonanomi et al [13], wherein the synovial retention of the liposomes improved on increasing their size. This was supported by a study by Bonanomi et al [13], wherein the synovial retention of the liposomes improved on increasing their size.…”

mentioning

confidence: 62%

“…The size of liposomes was found to affect the pharmacokinetics and therapeutic effect of the entrapped dexamethasone palmitate when administered intra-articularly in rabbits with antigen induced arthritis [13]. The larger sized liposomes (diameter 750 nm) were found to be more effective than the smaller ones (diameter 160 nm) which, in turn, were found to be more effective than the free drug.…”

Section: Dexamethasone Palmitatementioning

confidence: 99%

“…Liposomal delivery of the drug was found to alter its biodistribution [14]. The liposomal formulation proved to be better therapeutically also [13]. The liposomal formulation proved to be better therapeutically also [13].…”

Section: Methotrexatementioning

confidence: 99%

See 2 more Smart Citations

Use of Liposomal Drugs in the Treatment of Rheumatoid Arthritis

Chopra¹,

Gulati²,

Singh³

et al. 2008

CRR

View full text Add to dashboard Cite

Rheumatoid arthritis is an autoimmune disease that results in joint deformity and disability. Conventional nonsteroidal anti-inflammatory drugs (NSAIDs), steroids and disease modifying antirheumatic drugs (DMARD's) are used for its treatment. Unconventional therapies, like enzyme oligodeoxy nucleotides, boron neutron capture therapy & radioisotopes are also being tried. The use of all these drugs is limited by a number of adverse effects. These side effects have been overcome to a large extent by the use of liposomes as delivery systems. This review presents rationale for the use of liposomes for the treatment of arthritis. Systemic as well as intra-articular delivery of liposome encapsulated anti-arthritic drugs is discussed. Success and limitations of this approach are also discussed by taking examples of different drug classes. PATHOPHYSIOLOGY OF RHEUMATOID ARTHRI-TISRheumatoid arthritis is initiated by an autoimmune response triggered by some unknown antigens. A self-reactive immune cell (a T or B cell programmed to attack a selfprotein) can be activated on infection with common bacteria or virus [3]. Several bacteria have been implicated in the initiation of rheumatoid arthritis including streptococcus, mycoplasma, borrelia and retrovirus.

show abstract

mentioning

confidence: 62%

Section: Dexamethasone Palmitatementioning

confidence: 99%

See 1 more Smart Citation

Use of Liposomal Drugs in the Treatment of Rheumatoid Arthritis

Chopra¹,

Gulati²,

Singh³

et al. 2008

CRR

View full text Add to dashboard Cite

show abstract

“…It was also observed that about 36% of the liposomal dexamethasone palmitate was still in the synovial fluid after 6 h of injection while triamcinolone acetonide had fully disappeared from the joints till that time. Increase in diameter of liposomal vesicles was shown to improve the retention time of drug [96]. …”

Section: Drug Delivery Systems For Ra Therapymentioning

confidence: 99%

Application of Liposomes in Treatment of Rheumatoid Arthritis: Quo Vadis

Kapoor

Singh

Gulati

et al. 2014

The Scientific World Journal

103

View full text Add to dashboard Cite

The most common treatments for rheumatoid arthritis include nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, disease modifying antirheumatic drugs (DMARDs), and some biological agents. However, none of the treatments available is able to achieve the ultimate goal of treatment, that is, drug-free remission. This limitation has shifted the focus of treatment to delivery strategies with an ability to deliver the drugs into the synovial cavity in the proper dosage while mitigating side effects to other tissues. A number of approaches like microemulsions, microspheres, liposomes, microballoons, cocrystals, nanoemulsions, dendrimers, microsponges, and so forth, have been used for intrasynovial delivery of these drugs. Amongst these, liposomes have proven to be very effective for retaining the drug in the synovial cavity by virtue of their size and chemical composition. The fast clearance of intra-synovially administered drugs can be overcome by use of liposomes leading to increased uptake of drugs by the target synovial cells, which in turn reduces the exposure of nontarget sites and eliminates most of the undesirable effects associated with therapy. This review focuses on the use of liposomes in treatment of rheumatoid arthritis and summarizes data relating to the liposome formulations of various drugs. It also discusses emerging trends of this promising technology.

show abstract

“…Dex-liposomes, reported as early as the late 1980s (50), have been evaluated in numerous acute and chronic conditions. In models of ALI, pretreatment of animals with liposomal Dex inhibited granulocyte influx and inflammatory mediator expression as well as (51) or even better than (52) treatment with the free drug.…”

Section: Nanocarrier-mediated Delivery Of Anti-inflammatory Agentsmentioning

confidence: 99%

Nanocarriers for Vascular Delivery of Anti-Inflammatory Agents

Howard

Hood

Zern

et al. 2014

Annu. Rev. Pharmacol. Toxicol.

View full text Add to dashboard Cite

There is a need for improved treatment of acute vascular inflammation in conditions such as ischemia-reperfusion injury, acute lung injury, sepsis, and stroke. The vascular endothelium represents an important therapeutic target in these conditions. Furthermore, some anti-inflammatory agents (AIAs) (e.g., biotherapeutics) require precise delivery into subcellular compartments. In theory, optimized delivery to the desired site of action may improve the effects and enable new mechanisms of action of these AIAs. Diverse nanocarriers (NCs) and strategies for targeting them to endothelial cells have been designed and explored for this purpose. Studies in animal models suggest that delivery of AIAs using NCs may provide potent and specific molecular interventions in inflammatory pathways. However, the industrial development and clinical translation of complex NC-AIA formulations are challenging. Rigorous analysis of therapeutic/side effect and benefit/cost ratios is necessary to identify and optimize the approaches that may find clinical utility in the management of acute inflammation.

show abstract

Studies of pharmacokinetics and therapeutic effects of glucocorticoids entrapped in liposomes after intraarticular application in healthy rabbits and in rabbits with antigen-induced arthritis

Cited by 58 publications

References 17 publications

Use of Liposomal Drugs in the Treatment of Rheumatoid Arthritis

Use of Liposomal Drugs in the Treatment of Rheumatoid Arthritis

Application of Liposomes in Treatment of Rheumatoid Arthritis: Quo Vadis

Nanocarriers for Vascular Delivery of Anti-Inflammatory Agents

Contact Info

Product

Resources

About